Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.04 is 549% above its 1-year average of -0.01, near the high end of its 1-year range (-0.06–0.04).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly debt to equity ratio; no daily interpolation.
Limited quarterly history available
Debt to Equity needs at least three reported quarters before a meaningful chart is shown.
DEBT TO EQUITY RATIO
0.04
DEBT TO EQUITY RATIO AVG TTM
N/A
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 564 covered companies
CURRENT VS SECTOR MEDIAN
-66.96%
vs the sector median at left
Avalyn Pharma Inc. Common Stock
Market Cap
$1.16B
Debt to Equity Ratio
0.04
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.13B
Debt to Equity Ratio
0.00
TTM Avg
0.05
3Y Avg
0.03
5Y Avg
0.02
Market Cap
$1.15B
Debt to Equity Ratio
0.83
TTM Avg
0.81
3Y Avg
0.86
5Y Avg
0.88
Market Cap
$1.12B
Debt to Equity Ratio
19.79
TTM Avg
4.04
3Y Avg
3.72
5Y Avg
3.78
Market Cap
$1.12B
Debt to Equity Ratio
0.90
TTM Avg
0.86
3Y Avg
0.72
5Y Avg
0.55
Market Cap
$1.18B
Debt to Equity Ratio
0.15
TTM Avg
1.67
3Y Avg
1.15
5Y Avg
0.83
Market Cap
$1.09B
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$1.09B
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.01
5Y Avg
0.02
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Avalyn Pharma Inc. Common Stock (AVLN) | $1.16B | 0.04 | N/A | N/A | N/A |
| OPKO Health, Inc. (OPK)vs › | $1.15B | 0.33 | 0.35 | 0.29 | 0.25 |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.13B | 0.00 | 0.05 | 0.03 | 0.02 |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 0.83 | 0.81 | 0.86 | 0.88 |
| Harrow Health, Inc. (HROW)vs › | $1.12B | 19.79 | 4.04 | 3.72 | 3.78 |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 0.90 | 0.86 | 0.72 | 0.55 |
| Nektar Therapeutics (NKTR)vs › | $1.18B | 0.15 | 1.67 | 1.15 | 0.83 |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | 0.00 | 0.00 | 0.00 | 0.00 |
| IRadimed Corporation (IRMD)vs › | $1.09B | 0.00 | 0.00 | 0.01 | 0.02 |
| MannKind Corporation (MNKD)vs › | $1.21B | N/A | 0.97 | 0.56 | 0.37 |
Debt/Equity
0.04
Current Ratio
33.10
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.04 |
| 2026-03-31 | -0.06 |
